Clinical Trial Update: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer [Phase 2]

View source ↗

Summary

A single-arm Phase II trial evaluating adjuvant endocrine therapy combined with pertuzumab and trastuzumab in patients with anatomic stage I hormone receptor-po…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Hormone Receptor-positive Breast Cancer
• Invasive Breast Cancer
• Node-negative Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: HER2-positive Breast Cancer, Invasive Carcinoma of the Breast | Phase 2 | Status: ACTIVE_NOT_RECRUITING